{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:01:36Z","timestamp":1793883696057,"version":"4.7.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG046205"],"award-info":[{"award-number":["R01AG046205"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R37AG027924"],"award-info":[{"award-number":["R37AG027924"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["RF1AG051504"],"award-info":[{"award-number":["RF1AG051504"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["P50AG016574"],"award-info":[{"award-number":["P50AG016574"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Apolipoprotein E (\n                    <jats:italic>APOE<\/jats:italic>\n                    ) \u03b54 allele is the strongest genetic risk factor for late-onset Alzheimer\u2019s disease mainly by modulating amyloid-\u03b2 pathology.\n                    <jats:italic>APOE<\/jats:italic>\n                    \u03b54 is also shown to exacerbate neurodegeneration and neuroinflammation in a tau transgenic mouse model. To further evaluate the association of\n                    <jats:italic>APOE<\/jats:italic>\n                    genotype with the presence and severity of tau pathology, we express human tau via an adeno-associated virus gene delivery approach in human\n                    <jats:italic>APOE<\/jats:italic>\n                    targeted replacement mice. We find increased hyperphosphorylated tau species, tau aggregates, and behavioral abnormalities in mice expressing\n                    <jats:italic>APOE<\/jats:italic>\n                    \u03b52\/\u03b52. We also show that in humans, the\n                    <jats:italic>APOE<\/jats:italic>\n                    \u03b52 allele is associated with increased tau pathology in the brains of progressive supranuclear palsy (PSP) cases. Finally, we identify an association between the\n                    <jats:italic>APOE<\/jats:italic>\n                    \u03b52\/\u03b52 genotype and risk of tauopathies using two series of pathologically-confirmed cases of PSP and corticobasal degeneration. Our data together suggest\n                    <jats:italic>APOE<\/jats:italic>\n                    \u03b52 status may influence the risk and progression of tauopathy.\n                  <\/jats:p>","DOI":"10.1038\/s41467-018-06783-0","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T10:20:06Z","timestamp":1539685206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":134,"title":["APOE \u03b52 is associated with increased tau pathology in primary tauopathy"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8648-9422","authenticated-orcid":false,"given":"Na","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra J.","family":"Van Ingelgom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Linares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishe","family":"Kurti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Heckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy N.","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka A.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia N.","family":"Attrebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Petrucelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Fryer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew K.","family":"Wszolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neill R.","family":"Graff-Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Caselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica Y.","family":"Sanchez-Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Rademakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7379-2545","authenticated-orcid":false,"given":"Melissa E.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8868-9700","authenticated-orcid":false,"given":"Shunsuke","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7189-7917","authenticated-orcid":false,"given":"Dennis W.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen A.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,22]]},"reference":[{"key":"6783_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow, K., de Leon, M. J. & Zetterberg, H. Alzheimer\u2019s disease. Lancet 368, 387\u2013403 (2006).","journal-title":"Lancet"},{"key":"6783_CR2","first-page":"271","volume":"387","author":"RL Neve","year":"1986","unstructured":"Neve, R. L., Harris, P., Kosik, K. S., Kurnit, D. M. & Donlon, T. A. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res. 387, 271\u2013280 (1986).","journal-title":"Brain Res."},{"key":"6783_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nrn2620","volume":"10","author":"G Bu","year":"2009","unstructured":"Bu, G. Apolipoprotein E and its receptors in Alzheimer\u2019s disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10, 333\u2013344 (2009).","journal-title":"Nat. Rev. Neurosci."},{"key":"6783_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu, C. C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 106\u2013118 (2013).","journal-title":"Nat. Rev. Neurol."},{"key":"6783_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.biopsych.2017.03.003","volume":"83","author":"N Zhao","year":"2018","unstructured":"Zhao, N., Liu, C. C., Qiao, W. & Bu, G. Apolipoprotein E, receptors, and modulation of Alzheimeras disease. Biol. Psychiatry 83, 347\u2013357 (2018).","journal-title":"Biol. Psychiatry"},{"key":"6783_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang, Y. & Mandelkow, E. Tau in physiology and pathology. Nat. Rev. Neurosci. 17, 5\u201321 (2016).","journal-title":"Nat. Rev. Neurosci."},{"key":"6783_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13024-017-0192-x","volume":"12","author":"CEG Leyns","year":"2017","unstructured":"Leyns, C. E. G. & Holtzman, D. M. Glial contributions to neurodegeneration in tauopathies. Mol. Neurodegener. 12, 50 (2017).","journal-title":"Mol. Neurodegener."},{"key":"6783_CR8","doi-asserted-by":"publisher","first-page":"a009258","DOI":"10.1101\/cshperspect.a009258","volume":"2","author":"DW Dickson","year":"2012","unstructured":"Dickson, D. W. Parkinsonas disease and parkinsonism: neuropathology. Cold Spring Harb. Perspect. Med. 2, a009258 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"6783_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11940-016-0422-5","volume":"18","author":"R Lamb","year":"2016","unstructured":"Lamb, R., Rohrer, J. D., Lees, A. J. & Morris, H. R. Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options. Curr. Treat. Options Neurol. 18, 42 (2016).","journal-title":"Curr. Treat. Options Neurol."},{"key":"6783_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/hmg\/8.4.711","volume":"8","author":"M Baker","year":"1999","unstructured":"Baker, M. et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 8, 711\u2013715 (1999).","journal-title":"Hum. Mol. Genet."},{"key":"6783_CR11","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1212\/WNL.56.12.1702","volume":"56","author":"H Houlden","year":"2001","unstructured":"Houlden, H. et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 56, 1702\u20131706 (2001).","journal-title":"Neurology"},{"key":"6783_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3233\/JAD-150555","volume":"49","author":"P Pastor","year":"2016","unstructured":"Pastor, P. et al. MAPT H1 haplotype is associated with late-onset Alzheimer\u2019s disease risk in APOEvarepsilon4 noncarriers: results from the Dementia Genetics Spanish Consortium. J. Alzheimers Dis. 49, 343\u2013352 (2016).","journal-title":"J. Alzheimers Dis."},{"key":"6783_CR13","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.neurobiolaging.2012.06.015","volume":"34","author":"M Colom-Cadena","year":"2013","unstructured":"Colom-Cadena, M. et al. MAPT H1 haplotype is associated with enhanced alpha-synuclein deposition in dementia with Lewy bodies. Neurobiol. Aging 34, 936\u2013942 (2013).","journal-title":"Neurobiol. Aging"},{"key":"6783_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi, Y. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523\u2013527 (2017).","journal-title":"Nature"},{"key":"6783_CR15","doi-asserted-by":"publisher","first-page":"6198","DOI":"10.1093\/hmg\/ddv336","volume":"24","author":"C Cook","year":"2015","unstructured":"Cook, C. et al. Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model. Hum. Mol. Genet. 24, 6198\u20136212 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"6783_CR16","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.neurobiolaging.2013.12.023","volume":"35","author":"C Cook","year":"2014","unstructured":"Cook, C. et al. Severe amygdala dysfunction in a MAPT transgenic mouse model of frontotemporal dementia. Neurobiol. Aging 35, 1769\u20131777 (2014).","journal-title":"Neurobiol. Aging"},{"key":"6783_CR17","doi-asserted-by":"publisher","first-page":"11183","DOI":"10.1073\/pnas.91.23.11183","volume":"91","author":"WJ Strittmatter","year":"1994","unstructured":"Strittmatter, W. J. et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc. Natl Acad. Sci. USA 91, 11183\u201311186 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6783_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1212\/01.WNL.0000044340.37138.A9","volume":"60","author":"Y Tsuboi","year":"2003","unstructured":"Tsuboi, Y., Josephs, K. A., Cookson, N. & Dickson, D. W. APOE E4 is a determinant for Alzheimer type pathology in progressive supranuclear palsy. Neurology 60, 240\u2013245 (2003).","journal-title":"Neurology"},{"key":"6783_CR19","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/hmg\/ddh138","volume":"13","author":"AM Pittman","year":"2004","unstructured":"Pittman, A. M. et al. The structure of the tau haplotype in controls and in progressive supranuclear palsy. Hum. Mol. Genet. 13, 1267\u20131274 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"6783_CR20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/ana.1159","volume":"50","author":"WK Liu","year":"2001","unstructured":"Liu, W. K. et al. Relationship of the extended tau haplotype to tau biochemistry and neuropathology in progressive supranuclear palsy. Ann. Neurol. 50, 494\u2013502 (2001).","journal-title":"Ann. Neurol."},{"key":"6783_CR21","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1136\/jmg.2005.031377","volume":"42","author":"AM Pittman","year":"2005","unstructured":"Pittman, A. M. et al. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J. Med. Genet. 42, 837\u2013846 (2005).","journal-title":"J. Med. Genet."},{"key":"6783_CR22","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/1531-8249(200003)47:3<374::AID-ANA15>3.0.CO;2-8","volume":"47","author":"E Di Maria","year":"2000","unstructured":"Di Maria, E. et al. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann. Neurol. 47, 374\u2013377 (2000).","journal-title":"Ann. Neurol."},{"key":"6783_CR23","doi-asserted-by":"publisher","first-page":"11445","DOI":"10.1523\/JNEUROSCI.1972-08.2008","volume":"28","author":"DR Riddell","year":"2008","unstructured":"Riddell, D. R. et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J. Neurosci. 28, 11445\u201311453 (2008).","journal-title":"J. Neurosci."},{"key":"6783_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1750-1326-8-13","volume":"8","author":"JD Ulrich","year":"2013","unstructured":"Ulrich, J. D. et al. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol. Neurodegener. 8, 13 (2013).","journal-title":"Mol. Neurodegener."},{"key":"6783_CR25","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.neurobiolaging.2009.05.011","volume":"32","author":"PM Sullivan","year":"2011","unstructured":"Sullivan, P. M. et al. Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol. Aging 32, 791\u2013801 (2011).","journal-title":"Neurobiol. Aging"},{"key":"6783_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.neurobiolaging.2004.09.003","volume":"26","author":"J Poirier","year":"2005","unstructured":"Poirier, J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer\u2019s disease. Neurobiol. Aging 26, 355\u2013361 (2005).","journal-title":"Neurobiol. Aging"},{"key":"6783_CR27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/ana.24326","volume":"77","author":"KL Rasmussen","year":"2015","unstructured":"Rasmussen, K. L., Tybjaerg-Hansen, A., Nordestgaard, B. G. & Frikke-Schmidt, R. Plasma levels of apolipoprotein E and risk of dementia in the general population. Ann. Neurol. 77, 301\u2013311 (2015).","journal-title":"Ann. Neurol."},{"key":"6783_CR28","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1161\/ATVBAHA.116.307023","volume":"36","author":"RW Mahley","year":"2016","unstructured":"Mahley, R. W. Central nervous system lipoproteins: ApoE and regulation of cholesterol metabolism. Arterioscler. Thromb. Vasc. Biol. 36, 1305\u20131315 (2016).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"6783_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1001\/archneur.58.3.373","volume":"58","author":"N Andreasen","year":"2001","unstructured":"Andreasen, N. et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 58, 373\u2013379 (2001).","journal-title":"Arch. Neurol."},{"key":"6783_CR30","doi-asserted-by":"publisher","first-page":"13110","DOI":"10.1523\/JNEUROSCI.2569-11.2011","volume":"31","author":"K Yamada","year":"2011","unstructured":"Yamada, K. et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci. 31, 13110\u201313117 (2011).","journal-title":"J. Neurosci."},{"key":"6783_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-016-0143-y","volume":"12","author":"Y Wang","year":"2017","unstructured":"Wang, Y. et al. The release and trans-synaptic transmission of Tau via exosomes. Mol. Neurodegener. 12, 5 (2017).","journal-title":"Mol. Neurodegener."},{"key":"6783_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13024-016-0138-8","volume":"11","author":"TM Achariyar","year":"2016","unstructured":"Achariyar, T. M. et al. Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Mol. Neurodegener. 11, 74 (2016).","journal-title":"Mol. Neurodegener."},{"key":"6783_CR33","first-page":"0527","volume":"24","author":"WJ Brecht","year":"2004","unstructured":"Brecht, W. J. et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J. Neurosci. 24, 0527\u20132534 (2004).","journal-title":"J. Neurosci."},{"key":"6783_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.neurobiolaging.2015.09.011","volume":"37","author":"JM Farfel","year":"2016","unstructured":"Farfel, J. M., Yu, L., De Jager, P. L., Schneider, J. A. & Bennett, D. A. Association of APOE with tau-tangle pathology with and without beta-amyloid. Neurobiol. Aging 37, 19\u201325 (2016).","journal-title":"Neurobiol. Aging"},{"key":"6783_CR35","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/mds.27198","volume":"32","author":"S Koga","year":"2017","unstructured":"Koga, S. et al. Cognitive impairment in progressive supranuclear palsy is associated with tau burden. Mov. Disord. 32, 1772\u20131779 (2017).","journal-title":"Mov. Disord."},{"key":"6783_CR36","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1212\/WNL.45.9.1764","volume":"45","author":"M Tabaton","year":"1995","unstructured":"Tabaton, M. et al. Apolipoprotein E epsilon 4 allele frequency is not increased in progressive supranuclear palsy. Neurology 45, 1764\u20131765 (1995).","journal-title":"Neurology"},{"key":"6783_CR37","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/ana.410410522","volume":"41","author":"K Ikeda","year":"1997","unstructured":"Ikeda, K. et al. A subset of senile dementia with high incidence of the apolipoprotein E epsilon2 allele. Ann. Neurol. 41, 693\u2013695 (1997).","journal-title":"Ann. Neurol."},{"key":"6783_CR38","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","volume":"128","author":"JF Crary","year":"2014","unstructured":"Crary, J. F. et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128, 755\u2013766 (2014).","journal-title":"Acta Neuropathol."},{"key":"6783_CR39","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s004010050886","volume":"96","author":"E Ghebremedhin","year":"1998","unstructured":"Ghebremedhin, E. et al. Argyrophilic grain disease is associated with apolipoprotein E epsilon 2 allele. Acta Neuropathol. 96, 222\u2013224 (1998).","journal-title":"Acta Neuropathol."},{"key":"6783_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1750-3639.2002.tb00421.x","volume":"12","author":"T Togo","year":"2002","unstructured":"Togo, T., Cookson, N. & Dickson, D. W. Argyrophilic grain disease: neuropathology, frequency in a dementia brain bank and lack of relationship with apolipoprotein E. Brain Pathol. 12, 45\u201352 (2002).","journal-title":"Brain Pathol."},{"key":"6783_CR41","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/ng.859","volume":"43","author":"GU Hoglinger","year":"2011","unstructured":"Hoglinger, G. U. et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat. Genet. 43, 699\u2013705 (2011).","journal-title":"Nat. Genet."},{"key":"6783_CR42","doi-asserted-by":"crossref","first-page":"9077","DOI":"10.1016\/S0021-9258(19)52510-8","volume":"256","author":"KH Weisgraber","year":"1981","unstructured":"Weisgraber, K. H., Rall, S. C. Jr. & Mahley, R. W. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J. Biol. Chem. 256, 9077\u20139083 (1981).","journal-title":"J. Biol. Chem."},{"key":"6783_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.neuron.2014.08.048","volume":"84","author":"CC Liu","year":"2014","unstructured":"Liu, C. C. et al. Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer\u2019s disease. Neuron 84, 63\u201377 (2014).","journal-title":"Neuron"},{"key":"6783_CR44","first-page":"332ra344","volume":"8","author":"CC Liu","year":"2016","unstructured":"Liu, C. C. et al. Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-beta clearance and aggregation in Alzheimer\u2019s disease. Sci. Transl. Med. 8, 332ra344 (2016).","journal-title":"Sci. Transl. Med."},{"key":"6783_CR45","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00401-016-1580-y","volume":"132","author":"M Shinohara","year":"2016","unstructured":"Shinohara, M. et al. Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer\u2019s disease. Acta Neuropathol. 132, 225\u2013234 (2016).","journal-title":"Acta Neuropathol."},{"key":"6783_CR46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.neuron.2017.09.003","volume":"96","author":"N Zhao","year":"2017","unstructured":"Zhao, N. et al. Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes. Neuron 96, 115\u2013129.e5 (2017).","journal-title":"Neuron"},{"key":"6783_CR47","doi-asserted-by":"publisher","first-page":"e67680","DOI":"10.1371\/journal.pone.0067680","volume":"8","author":"P Chakrabarty","year":"2013","unstructured":"Chakrabarty, P. et al. Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain. PLoS ONE 8, e67680 (2013).","journal-title":"PLoS ONE"},{"key":"6783_CR48","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.neuron.2013.07.046","volume":"80","author":"K Yanamandra","year":"2013","unstructured":"Yanamandra, K. et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402\u2013414 (2013).","journal-title":"Neuron"},{"key":"6783_CR49","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/brain\/awu046","volume":"137","author":"M Shinohara","year":"2014","unstructured":"Shinohara, M. et al. Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer\u2019s disease. Brain 137, 1533\u20131549 (2014).","journal-title":"Brain"},{"key":"6783_CR50","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1212\/WNL.44.11.2015","volume":"44","author":"JJ Hauw","year":"1994","unstructured":"Hauw, J. J. et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 44, 2015\u20132019 (1994).","journal-title":"Neurology"},{"key":"6783_CR51","unstructured":"Dickson, D. W., Hauw, J.-J., Agid, Y. and Litvan, I. in Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders 2nd edn (eds Dickon, D. W. & Weller, R. O.) Ch. 15 (Wiley-Blackwell, Chichester, 2011)."},{"key":"6783_CR52","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239\u2013259 (1991).","journal-title":"Acta Neuropathol."},{"key":"6783_CR53","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal, D. R., Rub, U., Orantes, M. & Braak, H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791\u20131800 (2002).","journal-title":"Neurology"},{"key":"6783_CR54","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/brain\/awv050","volume":"138","author":"ME Murray","year":"2015","unstructured":"Murray, M. E. et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer\u2019s disease spectrum. Brain 138, 1370\u20131381 (2015).","journal-title":"Brain"},{"key":"6783_CR55","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/mds.26809","volume":"32","author":"S Koga","year":"2017","unstructured":"Koga, S. et al. Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. Mov. Disord. 32, 246\u2013255 (2017).","journal-title":"Mov. Disord."},{"key":"6783_CR56","doi-asserted-by":"publisher","first-page":"7607","DOI":"10.1073\/pnas.0900688106","volume":"106","author":"YJ Zhang","year":"2009","unstructured":"Zhang, Y. J. et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc. Natl Acad. Sci. USA 106, 7607\u20137612 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6783_CR57","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/jnen\/61.11.935","volume":"61","author":"DW Dickson","year":"2002","unstructured":"Dickson, D. W. et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J. Neuropathol. Exp. Neurol. 61, 935\u2013946 (2002).","journal-title":"J. Neuropathol. Exp. Neurol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06783-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06783-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06783-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T14:22:44Z","timestamp":1671546164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06783-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,22]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["6783"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-06783-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,22]]},"assertion":[{"value":"11 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4388"}}